SynthesisPloS one2025
Oral pre-exposure prophylaxis retention among men who have sex with men and transgender persons: Systematic review and meta-analysis.
Synthesis in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Successful implementation of oral pre-exposure prophylaxis (PrEP) requires retention in PrEP care among those with an increased likelihood of HIV. This study aimed to estimate the proportion of retention on PrEP and extent to which variability in PrEP retention is associated with population-, program-, and study-specific characteristics among men who have sex with men (MSM) and transgender persons (TGP). We performed a systematic review and meta-analysis examining PrEP studies and conference abstracts retrieved from the PubMed and Ovid online databases, capturing demonstration projects or observational studies published from January 1, 2010 to March 24, 2021. We included 84 studies (totaling 90 study "cohorts" analyzed) that reported on the retention of oral PrEP for HIV and included predominantly MSM and TGP. The proportion of retained participants was obtained from each study and used to estimate the cumulative probability of being retained on PrEP and the loss of PrEP retention rate over time via a random-effects meta-analysis survival model. We examined sources of heterogeneity by including study-level covariates in this model. The pooled cumulative probability of PrEP retention was 77.0%, 64.7%, 48.5%, and 24.1% at 6, 12, 24, and 60 months, respectively. Loss of PrEP retention rates were significantly (p < 0.05) lower in studies from Europe, Australia and multiple regions (vs. North America), and with ≥3-monthly follow-up (vs. < 3). Rates were significantly higher in studies from Africa (vs. North America), with lower median age, higher proportions of non-MSM/TGP participants, higher proportions of participants with unspecified (vs. mixed) ethnicity, with unspecified (vs. daily) PrEP regimen, free-of-charge (vs. unspecified) STI testing, whose data were from conference abstracts (vs. peer-reviewed papers), and that were more recent. In conclusion, oral PrEP retention decreased over time and differed across population-, program-, and study-specific characteristics. The heterogeneity across studies highlights PrEP implementation challenges and the need for tailored retention strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.